Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Oova, Inc.'s Study Harnesses Hormone Data and Age to Precisely Determine Cycle Day within the Menstrual Cycle
  • USA - English


News provided by

Oova

Aug 03, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Oova
Oova

Oova's Advanced Technology Yet Again Challenges What We Think We Know About Women's Reproductive Health

NEW YORK, Aug. 3, 2023  /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled "Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle." Conducted by esteemed scientists and co-authors, led by Dr. Amy Divaraniya, PhD founder of Oova, Inc., Dr. Mark B. Woodland, MD, Chair of Obstetrics and Gynecology at Tower Health, and Elinor Hills, content and brand lead at Oova, Inc, their discoveries bring a new understanding of the female reproductive cycle, particularly women with irregular periods, and confirms just how advanced and accurate remote hormone tracking has become.

Adding to Oova's extensive collection of research and data on women's hormone levels, the study challenges the standard norms used for comparison and disproves the assumption of a 28-day reproductive cycle. Shedding light on this inaccuracy and working towards a greater understanding of the female reproductive cycle. The study illustrates that the remote hormone monitoring platform can now analyze women's cycles and pinpoint where an individual is in their cycle with minimal data points and the technology within Oova's AI-powered app.

Oova, developed by Dr. Divaraniya, is a testing system that allows users to track their luteinizing hormone (LH) and pregnanediol-3-glucuronide (PdG) fluctuations throughout their cycles. The platform collects quantitative hormone measurements through urine to identify users' unique fertile windows and predict ovulation. In this study, the Oova team evaluated hormone data from 4,123 cycles across 1,233 users, analyzing and tracking the LH and PdG via urine tests throughout menstrual cycles across different age groups.

Key Findings from the Study Include:

1. While 23.67% of women self-reported they had a 28-day cycle, only 5.23% actually did. Population-level data showed that women typically expected their cycle to be longer than it was.

2. Oova's data challenged the assumption that a woman's follicular and luteal phases are of equal lengths and that ovulation occurs exactly in the middle. Instead, the follicular phase was generally longer than the luteal phase. Furthermore, the data revealed that as women age, the length of the follicular phase decreases, while the luteal phase increases.

3. Using Oova's hormone data to train their algorithm, Oova can now determine a woman's cycle day based on her age and hormone levels with 95% confidence. This is groundbreaking, as it allows for a thorough understanding of a woman's cycle, even if it's irregular.

"Our mission at Oova is to empower women with an accurate understanding of their reproductive health, giving them control on their journey to pregnancy. Further, our mission is to challenge the status quo and debunk widely accepted inaccuracies to set new standards in women's healthcare. This study is proof of our capabilities at Oova, and we can now say with confidence that at-home hormone monitoring offers more precise cycle tracking than textbook estimations, benefiting fertility planning, clinical management, and general health monitoring," says Oova founder and study leader, Dr. Amy Divaraniya.

Dr. Divaraniya developed the OOVA technology after her own 18-month struggle to get pregnant. Over-the-counter hormone tests were not conducive to tracking her irregular menstrual and ovulation cycle. She has created advanced technology, that provides a hormone monitoring solution for women facing cycle irregularities, a symptom that studies have shown affects more than 87% of the female population [reference link . Oova's data has been integral in discovering hormone patterns of Oova users in advanced maternal age. It has led to identifying hormone patterns that indicate patients' presentation of signs of reproductive disorders such as PCOS. This latest study represents a groundbreaking advancement, as it reveals the possibility of precisely pinpointing where a person is in their cycle using only one measure of LH and PdG, a capability previously unattainable. These and future Oova findings have the potential to fill significant gaps within reproductive healthcare and beyond.

In addition to Oova's consumer and clinician business, the company holds an ongoing study and research department. They are actively looking for partners to support their independent research. Past research collaborators include Massachusetts General Hospital, New Hope Fertility Center, and IRMS at St. Barnabas Hospital. If you're interested in collaborating on additional research projects, please reach out to the Oova team at [email protected].

For all media inquires, please contact Sara Spiegel at [email protected]
For general inquiries, please contact [email protected]

About Oova, Inc.:
Oova is the fertility translator that fully illuminates a woman's fertility, giving her and her care team the clearest steps to conception. Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to patients and healthcare providers. Oova's at-home urine test measures luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience. Oova has partnered with the leading fertility and women's health practices in the United States. To learn more, visit Oova's website.

Media Contact

Sara Spiegel, Oova, 937 478 9235, [email protected]

SOURCE Oova

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.